Unlock instant, AI-driven research and patent intelligence for your innovation.

Sanguisorba aglycone emulsion for injection and preparing method and use thereof

A kind of Sanyu aglycone, a technology for injection, applied in the field of medicine

Inactive Publication Date: 2017-05-03
SICHUAN YINGLU WEITE PHARMA TECH CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, so far, there has been no public report on the preparation of injectable emulsions using buretin as the active ingredient for the treatment and / or prevention of myelosuppression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sanguisorba aglycone emulsion for injection and preparing method and use thereof
  • Sanguisorba aglycone emulsion for injection and preparing method and use thereof
  • Sanguisorba aglycone emulsion for injection and preparing method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 Preparation of injection emulsion of the present invention

[0026] Prescription 1 (A): 1 g of eucalyptus aglycone, 300 g of soybean oil, 20 g of egg yolk lecithin, 8 g of glycerin, and 3500 mL of water.

[0027] Prescription 2 (B): 2 g of eucalyptus aglycone, 100 g of medium-chain triglycerides, 20 g of egg yolk lecithin, 10 g of glycerin, and 7000 mL of water.

[0028] Prescription 3 (C): 3 g of eucalyptus aglycone, 200 g of fish oil, 30 g of egg yolk lecithin, 10 g of glycerin, and 10500 mL of water.

[0029] Prescription 4 (D): 0.5g of eucalyptus aglycone, 300g of olive oil, 30g of egg yolk lecithin, 10g of glycerin, and 1750mL of water.

[0030] Prescription five (E): 6 g of eucalyptus aglycone, 300 g of ethyl oleate, 30 g of egg yolk lecithin, 10 g of glycerin, and 21000 mL of water.

[0031] Prescription 6 (F): 8 g of eucalyptus aglycone, 300 g of castor oil, 30 g of egg yolk lecithin, 10 g of glycerin, and 28000 mL of water.

[0032] Prescription...

experiment example 1

[0035] Experimental example 1 Quality evaluation of the preparation of buretin aglycon emulsion with different excipients

[0036] There are 9 experimental groups in this experiment. Take 1.0 g of eucalyptin, the oil phase, emulsifier, stabilizer and isotonic regulator as shown in Table 1 respectively, and then the eucalyptin, oil phase and emulsifier are in a weight ratio of 1:300: 20 mixed, dissolved in ethanol, decompressed and rotary evaporated to remove ethanol, according to the weight ratio of stellium aglycone: stabilizer: isotonic regulator 1:0.5:1, add stabilizer and isotonic regulator under high-speed stirring, add water to The concentration of eucalyptin in the emulsion is 0.3 mg / mL, high-speed shearing at 10,000 rpm for 5 min, high-pressure homogenization at 800 bar for 4 times, and autoclaving. Observe whether there is delamination, flocculation, sticking to the wall in the appearance, measure the particle size, measure Ke (measure the absorbance A of the emulsio...

experiment example 2

[0041] Experimental example 2 The effect of the dosage of excipients on the quality of burnet aglycone emulsion

[0042] There are 7 experimental groups in this experiment. Weigh burletin, soybean oil, and soybean lecithin (fixed burletin weight 0.6g) according to the weight ratio shown in Table 2, dissolve with ethanol, remove ethanol by rotary evaporation under reduced pressure, and remove burletin according to the weight ratio. Element: oleic acid: glycerin: 1:0.5:1 Add oleic acid and glycerin under high-speed stirring, add water until the concentration of eucalyptin in the emulsion is 0.3mg / mL, high-speed shearing at 10000rpm for 5min, high-pressure homogenization at 800bar pressure 4 times, autoclave. Observe whether there is delamination, flocculation, wall sticking on the appearance, measure the particle size, measure Ke, and the results are shown in Table 2.

[0043] Table 2 Quality Evaluation Results of Diyu Aglycone Emulsion

[0044]

[0045] Note: "+" means ye...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a sanguisorba aglycone emulsion for injection; the emulsion is a preparation prepared from the following raw materials and auxiliary materials: sanguisorba aglycone, oil for injection, an emulsifier, glycerol and water. Experimental results indicate that after the preparation prescription makes sanguisorba aglycone into the emulsion for injection, the emulsion for injection can significantly improve the number of peripheral blood leukocytes, neutrophils, erythrocytes, platelets, hemoglobins and bone marrow hematopoietic stem cells, and has obvious effects of treatment and / or prevention of myelosuppression.

Description

technical field [0001] The invention relates to an emulsion for injection of eucalyptus aglycone, a preparation method and application thereof, and belongs to the field of medicine. Background technique [0002] Myelosuppression is a clinically common hematopoietic system disease, which can occur in radiotherapy and / or chemotherapy of tumor diseases of various systems, radiation injury caused by ionizing radiation, viral hepatitis, parvovirus infection or drugs (chloramphenicol , benzene, sulfonamides, antiepileptics, sedatives, antithyroid drugs, antidiabetics, antimalarials, sleeping pills) and other factors. Bone marrow suppression can cause damage to the bone marrow microenvironment, hematopoietic stem cells, hematopoietic growth factors, etc., and the first, second or third lineage of granulocytes, erythrocytes, and megakaryocytes are inhibited. Agranulocytosis can cause serious infection; red blood cell decrease can cause severe anemia; platelet decrease can cause sev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/107A61K47/44A61K47/24A61K47/14A61K47/10A61K31/56A61P7/00
CPCA61K9/107A61K9/0019A61K31/56A61K47/10A61K47/14A61K47/24A61K47/44
Inventor 杨世林
Owner SICHUAN YINGLU WEITE PHARMA TECH CO LTD